What Is PRP Therapy and How Is It Used in Regenerative Medicine?

Platelet-rich plasma therapy, commonly called PRP, has become one of the most widely discussed treatments in regenerative medicine. Sports medicine physicians, orthopedic specialists, and regenerative clinics across the country use it for a range of conditions. Athletes, weekend warriors, and patients dealing with chronic joint pain often encounter PRP as an option. But what it actually is, how it works, and when it makes clinical sense versus when it does not are questions that deserve thorough answers. This article covers the biology of PRP, how it is prepared, how it is used clinically, and how it differs from stem cell therapy.

What PRP Actually Is

Platelets, Growth Factors, and Why They Matter

Blood is not a uniform fluid. It contains red blood cells, white blood cells, platelets, and plasma, each performing different functions. Platelets, which most people associate with clotting after a cut, carry far more biological machinery than their clotting role suggests.

Platelets contain structures called alpha granules, which store a dense collection of growth factors and signaling proteins. When platelets are activated, these granules release their contents into the surrounding tissue environment. The growth factors most relevant to tissue repair include platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), and epidermal growth factor (EGF).

Each of these molecules plays a distinct role in tissue biology. PDGF signals cells to proliferate and migrate toward injury sites. TGF-beta influences collagen production and tissue remodeling. VEGF promotes the formation of new blood vessels, which is important for delivering oxygen and nutrients to healing tissue. IGF-1 supports cell survival and growth. EGF promotes cellular regeneration.

Research suggests that concentrating these growth factors at an injury site may amplify the body’s own repair signals. Rather than introducing living cells, PRP therapy works by delivering a concentrated dose of the body’s natural signaling molecules to a specific anatomical location.

How PRP Is Derived from a Patient’s Own Blood

PRP is autologous, meaning it comes from the patient’s own blood. This eliminates rejection risk and keeps the treatment within a well-understood safety profile for most patients. The process begins with a standard venous blood draw, typically 30 to 60 milliliters depending on the protocol.

That blood sample is then placed in a centrifuge. Centrifugation spins the sample at carefully calibrated speeds that cause the different components to separate based on density. Red blood cells, being the heaviest, settle to the bottom. Platelet-poor plasma rises to the top. The platelet-rich layer, concentrated between these two zones, is carefully extracted.

The entire preparation process from blood draw to ready-to-inject PRP takes approximately 15 to 30 minutes depending on whether a single-spin or double-spin protocol is used. The resulting product is a small volume of plasma in which platelet concentration is significantly higher than in circulating blood.

The PRP Preparation Process

Blood Draw and Centrifugation

The draw volume required for PRP is typically modest, in the range of 30 to 60 milliliters, which is similar to what is collected for a routine blood panel. Patients in good health tolerate this volume without difficulty. The blood is collected into specialized tubes that may contain anticoagulants to prevent premature clotting during processing.

Some clinics use a single-spin centrifugation protocol, which produces a product in one cycle. Others use a double-spin approach, which involves a first spin to separate red blood cells, followed by a second spin at a different speed to further concentrate the platelet layer. Double-spin protocols generally yield a higher platelet concentration, though they also tend to increase white blood cell (leukocyte) content.

The preparation system used, including the tube type, spin speed, and spin duration, significantly affects the final composition of the PRP product. This is one reason why clinical results across PRP studies can be difficult to compare directly. Different preparation systems produce meaningfully different products.

What Concentration Means in PRP Therapy

Normal platelet concentration in whole blood ranges from approximately 150,000 to 400,000 platelets per microliter. A well-prepared PRP product may achieve concentrations of three to eight times this baseline, and some protocols aim for even higher concentrations.

Research suggests that concentration affects biological effect, though the relationship is not simply linear. One 2020 study cited in the literature identified an optimal platelet concentration of approximately 1,500 x 10 to the ninth per microliter for stimulating mesenchymal stem cell proliferation, and did not find markedly increased effect beyond that threshold. This suggests that more is not always better, and that protocol design matters for outcome.

Leukocyte content is another variable that affects PRP classification and clinical behavior. Leukocyte-rich PRP contains a higher proportion of white blood cells, which may amplify the inflammatory component of the preparation. Leukocyte-poor PRP (sometimes called pure PRP) has a lower white cell content and may be preferred for intra-articular injection, where excess inflammation can be counterproductive. Research on which formulation is most effective for which condition is ongoing, and physician judgment about formulation selection is part of the clinical decision.

How PRP Is Used Clinically

Joint and Tendon Applications

The most extensively studied clinical application for PRP is knee osteoarthritis. Multiple reviews and meta-analyses of clinical evidence suggest that intra-articular PRP injection, particularly leukocyte-poor formulations, may produce superior pain relief and functional improvement compared to hyaluronic acid injections and corticosteroid injections, especially in patients with mild to moderate osteoarthritis (Kellgren-Lawrence grades I through III).

Imaging guidance, typically ultrasound, allows the physician to deliver PRP directly into the joint space with accuracy. This matters because free-hand intra-articular injection carries a meaningful risk of missing the joint, particularly in smaller or more anatomically complex joints.

Tendinopathy is another well-studied application. Conditions including patellar tendinopathy (jumper’s knee), Achilles tendinopathy, rotator cuff tendinopathy, and lateral epicondylitis (tennis elbow) have been studied in PRP trials. Research suggests that PRP may support tendon tissue remodeling through PDGF-mediated and TGF-beta-mediated signaling pathways, and patients in some studies have reported meaningful symptom improvement compared to corticosteroid injection, particularly at longer follow-up intervals.

Imaging-guided delivery is especially important in tendon applications, where precise depot placement within the tendon or at the tendon-bone junction may influence therapeutic effect.

Soft Tissue and Wound Healing

Beyond joints and tendons, PRP has been studied in muscle tear recovery, ligament support, and wound healing contexts. The platelet growth factor cocktail that accelerates repair signaling in tendons follows similar biological logic in other soft tissue environments.

Research indicates that PDGF, TGF-beta, and VEGF released from activated platelets may accelerate tissue proliferation and extracellular matrix remodeling following acute soft tissue injury. Clinical use in this context is often considered off-label for musculoskeletal applications, and evidence quality varies significantly across studies.

Wound care applications of PRP have a longer clinical history than musculoskeletal applications, particularly in surgical and diabetic wound contexts. This evidence base provides some support for the broad tissue-level rationale underlying PRP use.

How PRP Fits Into a Broader Regenerative Plan

PRP does not have to stand alone. In many clinical protocols, PRP serves as one component of a broader regenerative approach. When combined with stem cell therapy, PRP’s growth factor payload may create a more supportive environment for the introduced MSCs, potentially enhancing their paracrine signaling activity. Some research into combined protocols suggests that sequencing PRP before or alongside stem cell delivery may support the cellular environment.

PRP and A2M (alpha-2-macroglobulin) therapy are sometimes used together in joint applications. A2M works by inhibiting the proteases that destroy cartilage matrix, while PRP delivers growth factors that signal repair. The combination targets both the destructive process and the reparative process simultaneously, a rationale that regenerative physicians may apply when designing individualized treatment plans.

Regenerative physicians assess each patient’s condition, health history, and treatment goals to determine whether PRP alone, PRP combined with other modalities, or a different approach altogether represents the most appropriate path.

What PRP Is Not

How It Differs from Stem Cell Therapy

PRP and stem cell therapy are frequently mentioned together in regenerative medicine contexts, and patients sometimes assume they are variations of the same thing. They are not. The distinction matters because it affects what each treatment may reasonably be expected to do.

Platelets are not stem cells. They are cell fragments involved in clotting and growth factor delivery. They do not replicate, they do not differentiate into other cell types, and they do not engage in the paracrine signaling that characterizes MSC-based therapy. PRP works by delivering a concentrated burst of growth factor signals to a target site. Stem cell therapy works by introducing living cells that interact with the local biological environment over a sustained period.

The two treatments have different mechanisms, different candidacy criteria, different delivery logistics, and potentially different time courses of effect. A physician may choose PRP, stem cell therapy, or a combination depending on the specific condition, its severity, the patient’s biology, and the treatment goals. Neither is universally superior. They address overlapping but distinct biological problems through different means.

Conditions Where PRP Is and Is Not Appropriate

Research and clinical evidence suggest that PRP tends to perform best in patients with early to moderate osteoarthritis. In severe cases with extensive bone-on-bone contact and minimal remaining cartilage, the growth factor environment created by PRP may have less biological substrate to work with. These patients may be better served by surgical evaluation or other interventions.

Certain contraindications to PRP exist. Active infection at or near the injection site is a clear contraindication, as introducing a growth factor-rich preparation into an infected area could theoretically support bacterial proliferation. Systemic infection or sepsis represents another contraindication. Patients taking anticoagulant medications require careful physician evaluation before PRP, as their platelet function may be altered.

Patients with platelet function disorders or thrombocytopenia (low platelet count) may not be appropriate candidates because the concentration step of PRP preparation depends on the patient having adequate baseline platelet levels and function.

The candidacy assessment at a physician-led practice reviews these factors thoroughly before a PRP procedure is recommended. An honest evaluation of whether PRP is likely to provide meaningful benefit given a patient’s specific condition and stage of progression is a foundational part of responsible regenerative care.

Sources

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.